In an open-label Phase II trial involving 267 patients with HER2-positive tumors across seven tumor cohorts (endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, CCA, pancreatic cancer, and others), ORR in all patients treated with the combination of anti-HER2 antibody and DNA topoisomerase I inhibitor, trastuzumab plus deruxtecan, was 37.1%, with a median PFS of 6.9 months and a median OS of 13.4 months [145]. The gene discussed is ERBB2; the disease is endometrial cancer.